Antiemesis, version 2.2017 featured updates to the NCCN guidelines

Michael J. Berger, David S. Ettinger, Jonathan Aston, Sally Barbour, Jason Bergsbaken, Philip J. Bierman, Debra Brandt, Dawn E. Dolan, Georgiana Ellis, Eun Jeong Kim, Steve Kirkegaard, Dwight D. Kloth, Ruth Lagman, Dean Lim, Charles Lawrence Loprinzi, Cynthia X. Ma, Victoria Maurer, Laura Boehnke Michaud, Lisle M. Nabell, Kim NoonanEric Roeland, Hope S. Rugo, Lee S. Schwartzberg, Bridget Scullion, John Timoney, Barbara Todaro, Susan G. Urba, Dorothy A. Shead, Miranda Hughes

Research output: Contribution to journalReview articlepeer-review

69 Scopus citations

Abstract

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Antiemesis address all aspects of management for chemotherapy-induced nausea and vomiting. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for Antiemesis, specifically those regarding carboplatin, granisetron, and olanzapine.

Original languageEnglish (US)
Pages (from-to)883-893
Number of pages11
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume15
Issue number7
DOIs
StatePublished - Jul 1 2017

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Antiemesis, version 2.2017 featured updates to the NCCN guidelines'. Together they form a unique fingerprint.

Cite this